⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2024Open Access

Supplementary Figure S3 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Ana Oaknin Sharad Ghamande Yuka Kasamatsu Marta Gil-Martín Juan Francisco Grau-Béjar Carmen García-Durán Masashi Sato Abdul Siddiqui Surendra Pal Chaudhary Yulia Vugmeyster Kosei Hasegawa

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S3. Patient-level concentration profile of bintrafusp alfa at Day 1 postdose.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oaknin et al. (2024) studied this question.

synapsesocial.com/papers/68e7681cb6db6435876dd048 https://doi.org/10.1158/1078-0432.25324503

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024
2Supplementary Figure S1 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024
3Supplementary Figure S1 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024
4Supplementary Figure S2 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024
5Supplementary Figure S2 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer2024